uniQure NV (FRA:UQ1)
€ 14.66 0 (0%) Market Cap: 814.57 Mil Enterprise Value: 462.08 Mil PE Ratio: 0 PB Ratio: 15.15 GF Score: 65/100

Uniqure NV at Stifel CNS Days (Virtual) Transcript

Mar 28, 2022 / 04:00PM GMT
Release Date Price: €15.05 (-1.73%)
Alex Thompson
Stifel Financial Corp. - Analyst

Hey, good afternoon, everyone. I'm Alex Thompson, an associate here at Stifel. It's my pleasure to introduce Matt Kapusta, CEO of uniQure. To start things off, maybe, Matt, you could give a brief update on uniQure and where you're at with hemophilia and Huntington's. And then we'll jump into some more in-depth questions. So, over to you.

Matt Kapusta
uniQure N.V. - CEO

Yeah, sure. So I guess as of this morning, our global partner, CSL, announced the acceptance of our MAA for our hemophilia B gene therapy by EMA. So it's now formally under review in EMA, so we're very excited about that. The guidance is from CSL that they will submit the BLA in the first half of this year. So that process is moving forward.

And then for Huntington's disease, another very exciting program, we currently have a couple of Phase 1/2 studies that are currently enrolling. The first one is a randomized, controlled study -- blinded study that is taking place in the United States.

And we recently announced that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot